Literature DB >> 15163503

Epidermal powder immunization: cellular and molecular mechanisms for enhancing vaccine immunogenicity.

Dexiang Chen1, Melissa Burger, Qili Chu, Ryan Endres, Cindy Zuleger, Hansi Dean, Lendon G Payne.   

Abstract

Epidermal powder immunization (EPI) of mice with an influenza vaccine elicited consistently a higher hemagglutination inhibition (HI) antibody titers than intramuscular (IM) injection using the same dose of vaccine. The epidermal Langerhans cells (LCs) at the site of EPI were found to play an important role in the immune responses. Indeed, depletion of LCs from the immunization site prior to EPI caused a significant reduction in the antibody response. Transfer of LCs isolated from the EPI sites to naive mice induced a robust antigen-specific antibody response. Cytokines produced by target site cells appear to be important for the augmented immune responses induced by EPI. LTR72, a genetically detoxified heat-labile toxin from Escherichia coli with a strong adjuvant effect in EPI, was found to bind the keratinocytes of the epidermis, but not the LCs, and caused the production of elevated TNF-alpha and IL-12 cytokines in emigrating epidermal cells. These results have important implications for the development of a more efficacious human influenza vaccine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163503     DOI: 10.1016/j.virusres.2004.02.027

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  6 in total

1.  Spray-freeze-drying of nanosuspensions: the manufacture of insulin particles for needle-free ballistic powder delivery.

Authors:  Heiko Schiffter; Jamie Condliffe; Sebastian Vonhoff
Journal:  J R Soc Interface       Date:  2010-06-02       Impact factor: 4.118

2.  GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates.

Authors:  Peter T Loudon; Eric J Yager; Debbie T Lynch; Amithi Narendran; Cristy Stagnar; Anthony M Franchini; James T Fuller; Phil A White; Julia Nyuandi; Clayton A Wiley; Michael Murphey-Corb; Deborah H Fuller
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

Review 3.  Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors:  J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

Review 4.  Delivery systems for intradermal vaccination.

Authors:  Y C Kim; C Jarrahian; D Zehrung; S Mitragotri; M R Prausnitz
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

5.  Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine.

Authors:  Nikolas T Weissmueller; Leanne Marsay; Heiko A Schiffter; Robert C Carlisle; Christine S Rollier; Robert K Prud'homme; Andrew J Pollard
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

Review 6.  Developments in the formulation and delivery of spray dried vaccines.

Authors:  Gaurav Kanojia; Rimko Ten Have; Peter C Soema; Henderik Frijlink; Jean-Pierre Amorij; Gideon Kersten
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.